{{ attach_library('entyviohcp/mechanism-styling') }}
<div data-page-id="MechanismOfAction" data-page-category="MechanismOfAction" class="page-content mechanism-content" >
    <div id="hero">
        <div>
            <picture>
                <source media="screen and (max-width: 959px)" srcset="{{ base_path ~ directory }}/images/hero/mobile-moa-shuya.png">
                    <source media="screen and (max-width: 9999px) and (min-width: 960px)" srcset="{{ base_path ~ directory }}/images/hero/desktop-moa-shuya.png">
                        <img src="{{ base_path ~ directory }}/images/hero/desktop-moa-shuya.png" alt="Patient.">
            </picture>
            <article>
                <div>
                    <h1>
                            Mechanism<br>
                            <strong>of Action</strong>
                        </h1>
                </div>

                <div>
                    <h2>
                            Made for <br>
                            <strong>Selectivity</strong>
                        </h2>
                </div>

                <div class="extra-list">
                    <p>Entyvio specifically binds to the α4β7 integrin and blocks the interaction between the α4β7 integrin and MAdCAM-1, which is mainly expressed on the GI tract endothelial cells.<sup>1-7</sup>
                    </p>
                </div>
            </article>
            <picture>
                <source media="screen and (max-width: 959px)" srcset="{{ base_path ~ directory }}/images/hero/mobile-moa-rhitu.png">
                    <source media="screen and (max-width: 9999px) and (min-width: 960px)" srcset="{{ base_path ~ directory }}/images/hero/desktop-moa-rhitu.png">
                        <img src="{{ base_path ~ directory }}/images/hero/desktop-moa-rhitu.png" alt="Healthcare professional.">
            </picture>

        </div>
    </div>
    <div id="first_section">
        <div id="indication_bar" class="close">
            <div>
                <div class="section">
                    <h3>For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be&nbsp;tolerated.</h3>
                </div>
            </div>
        </div>

        <div>
            <article>
                <div class="moa-intro">
                    <h2 class="border"><span>ENTYVIO WAS MADE FOR&nbsp;SELECTIVITY<sup>1‑6</sup></span></h2>
                    <div class="container" data-row="">
                        <div class="key-point" data-col="mobile-12 desktop-5">
                            <p>Entyvio helps address inflammation where it occurs—<span class="brand-secondary">the gut</span><sup>1</sup></p>
                        </div>
                        <div class="body-copy" data-col="mobile-12 desktop-7">
                            <p>Ulcerative colitis and Crohn's disease cause chronic inflammation of the gut, and infiltrating T‑lymphocytes cross the endothelium into the inflamed GI tissue.<sup>8</sup> Entyvio is the first and only gut‑selective biologic to focus its action on an inflammatory pathway in the gut.<sup>1-6</sup></p>
                        </div>
                    </div>
                    <div class="video-container" role="img" aria-label="Entyvio® (vedolizumab) mechanism of action video.">
                        <video class="video-js" data-account="1841264443001" data-player="SykGTiz2b" data-embed="default" controls="" data-video-id="6221186623001" data-video-title="Mechanism of Action"  data-playlist-id="" data-application-id="" width="960" height="540"></video>
                        <script src="https://players.brightcove.net/2574028764001/SykGTiz2b_default/index.min.js"></script>
                    </div>
                </div>
                <div class="moa-steps">
                    <h2 class="border"><span>THE ONLY GUT-SELECTIVE BIOLOGIC FOR UC AND CD<sup>1,5</sup></span></h2>
                    <div class="accordion-container">
                        <!-- ACCORDION STARTS -->
                        <div class="accordion" data-accordion-type="list">
                            <div class="accordion-list">
                                <ul aria-label="Accordion Label" class="accordion-controls">
                                    <li class="active" data-vitals-expansion="Lymphocytes cause inflammation">
                                        <button id="accordion_trigger_id_1" aria-controls="accordion_content_1" aria-expanded="true">
                                            Excess Lymphocytes cause inflammation<sup>1,8</sup>
                                            <span></span>
                                        </button>
                                        <div id="accordion_content_1" aria-hidden="false">
                                            <div class="content">
                                                <p>Lymphocytes migrate into the GI tissue. An increased number of infiltrating lymphocytes and other inflammatory cells in the gut is one of the contributors to the inflammatory response.<sup>1,8</sup></p>
                                            </div>
                                            <figure class="figure-content">
                                                <img src="{{ base_path ~ directory }}/images/graphics/desktop-lymphocytes-inflammation.png" alt="Inflammation in the gut due to excess lymphocyte migration in UC and Crohn's disease." title="Inflammation in the Gut">
                                                <figcaption>Artist rendition</figcaption>
                                            </figure>
                                        </div>
                                    </li>
                                    <li data-vitals-expansion="Lymphocytes enter gi tissue">
                                        <button id="accordion_trigger_id_2" aria-controls="accordion_content_2" aria-expanded="false">
                                            Certain Lymphocytes enter gi tissue<sup>1,7,8</sup>
                                            <span></span>
                                        </button>
                                        <div id="accordion_content_2" aria-hidden="true">
                                            <div class="content">
                                                <p>The interaction between α4β7 integrin expressed on a certain subset of T cells, and its ligand, MAdCAM-1, contributes to inflammation in the GI tissue.<sup>1,7,8</sup></p>
                                            </div>
                                            <figure class="figure-content">
                                                <img src="{{ base_path ~ directory }}/images/graphics/desktop-lymphocytes-gi-tissue.png" alt="Lymphocytes in the GI tissue." title="Lymphocytes in the GI Tissue">
                                                <figcaption>Artist rendition</figcaption>
                                            </figure>
                                            <div class="to_footnote">
                                                <p>GI = gastrointestinal; MAdCAM-1 = mucosal addressin cell adhesion molecule‑1.</p>
                                            </div>
                                        </div>
                                    </li>
                                    <li data-vitals-expansion="Entyvio blocks lymphocyte interaction">
                                        <button id="accordion_trigger_id_3" aria-controls="accordion_content_3" aria-expanded="false">
                                            Entyvio blocks lymphocyte interaction<sup>1</sup>
                                            <span></span>
                                        </button>
                                        <div id="accordion_content_3" aria-hidden="true">
                                            <div class="content">
                                                <p>Entyvio specifically binds to the α4β7 integrin and blocks the interaction between the α4β7 integrin and MAdCAM-1, which is mainly expressed on GI tract endothelial cells.<sup>1-7</sup></p>
                                            </div>
                                            <figure class="figure-content">
                                                <img src="{{ base_path ~ directory }}/images/graphics/desktop-lymphocytes-entyvio-blocks.png" alt="Mechanism of action for Entyvio® (vedolizumab)." title="Mechanism of Action for Entyvio® (vedolizumab)">
                                                <figcaption>Artist rendition</figcaption>
                                            </figure>
                                            <div class="to_footnote">
                                                <p>GI = gastrointestinal; MAdCAM-1 = mucosal addressin cell adhesion molecule‑1.</p>
                                            </div>
                                        </div>
                                    </li>
                                    <li data-vitals-expansion="Inflammation is reduced">
                                        <button id="accordion_trigger_id_4" aria-controls="accordion_content_4" aria-expanded="false">
                                            Inflammation is reduced<sup>1</sup>
                                            <span></span>
                                        </button>
                                        <div id="accordion_content_4" aria-hidden="true">
                                            <div class="content">
                                                <p>T-lymphocyte migration into the gut is inhibited and inflammation is reduced.<sup>1</sup></p>
                                            </div>
                                            <figure class="figure-content">
                                                <picture>
                                                    <source media="screen and (max-width: 959px)" srcset="{{ base_path ~ directory }}/images/graphics/desktop-lymphocytes-inflammation-reduced.png">
                                                    <source media="screen and (max-width: 9999px) and (min-width: 960px)" srcset="{{ base_path ~ directory }}/images/graphics/desktop-lymphocytes-inflammation-reduced.png">
                                                    <img src="{{ base_path ~ directory }}/images/graphics/desktop-lymphocytes-inflammation-reduced.png" alt="With Entyvio® (vedolizumab), gut inflammation is reduced." title="Reduced Gut Inflammation">
                                                </picture>
                                                <figcaption>Artist rendition</figcaption>
                                            </figure>
                                        </div>
                                    </li>
                                </ul>
                                <div class="footnote">GI = gastrointestinal; MAdCAM-1 = mucosal addressin cell adhesion molecule‑1.</div>
                            </div>
                            <div>
                                <figure class="desktop-image">
                                    <picture>
                                        <source media="screen and (max-width: 959px)" srcset="{{ base_path ~ directory }}/images/graphics/desktop-lymphocytes-inflammation.png">
                                        <source media="screen and (max-width: 9999px) and (min-width: 960px)" srcset="{{ base_path ~ directory }}/images/graphics/desktop-lymphocytes-inflammation.png">
                                        <img src="{{ base_path ~ directory }}/images/graphics/desktop-lymphocytes-inflammation.png" alt="Inflammation due to excess lymphocyte migration">
                                    </picture>
                                    <figcaption>Artist rendition</figcaption>
                                </figure>
                            </div>
                        </div>
                        <!-- ACCORDION ENDS -->
                    </div>
                </div>
                <div class="interior-bottom-cta">
                    <div class="cta-container" data-row="">
                        <div class="cta-1 cta" data-col="mobile-12 desktop-6">
                            <p>Crohn's Disease Data</p>
                            <a href="{{ base_path}}clinical-efficacy/crohns-disease/entyvio-placebo-trial" class="btn btn-secondary">SEE RESULTS IN CD</a>
                        </div>
                        <div class="cta-2 cta" data-col="mobile-12 desktop-6">
                            <p>Entyvio Safety Profile</p>
                            <a href="{{ base_path}}safety-profile" class="btn btn-secondary">VIEW SAFETY PROFILE</a>
                        </div>
                    </div>
                </div>
            </article>
        </div>
    </div>
    <div id="isi">
        <aside class="section">
            <article>
                <button class="fixed_isi_trigger" aria-expanded="false" aria-controls="fixed_isi" aria-label="ISI Expand Button">
                    <span></span>
                </button>
                <div class="isi-header">
                    <h2>Important Safety Information</h2>
                </div>
                <ul>
                    <li>ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.</li>

                    <li>Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.</li>

                    <li>Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.</li>

                    <li>Progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML is caused by the John Cunningham (JC) virus and typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported in the postmarketing setting (e.g., human immunodeficiency virus [HIV] infection with a CD4 count of 300 cells/mm<sup>3</sup> and prior and concomitant immunosuppression). Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.</li>

                    <li>There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.</li>

                    <li>Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.</li>

                    <li>Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.</li>
                </ul>

                <h2>Indications</h2>
                <h3>Adult Ulcerative Colitis (UC)</h3>
                <p>ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active UC.</p>

                <h3>Adult Crohn's Disease (CD)</h3>
                <p>ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active CD.</p>

                <p>Please see <a href="https://general.takedapharm.com/ENTYVIOPI" target="_blank" rel="noreferrer">full Prescribing Information</a>, including <a href="https://general.takedapharm.com/ENTYVIOMG" target="_blank" rel="noreferrer">Medication Guide</a>.</p>
            </article>
        </aside>

    </div>
    <div id="references">
        <div class="section">
            <article>
                <h3>References:</h3>

                <ol>
                    <li>Entyvio (vedolizumab) prescribing information. Takeda Pharmaceuticals.</li>
                    <li>Fedyk E, Wyant T, Yang LL, et al. <em>Inflamm Bowel Dis</em>. 2012;18(11):2107<span>-</span>2119.</li>
                    <li>Soler D, Chapman T, Yang LL, et al. <em>J Pharmacol Exp Ther</em>. 2009;330(3):864-875.</li>
                    <li>Wyant T, Leach T, Sankoh S, et al. <em>Gut</em>. 2015;64(1):77-83.</li>
                    <li>Wyant T, Fedyk E, Abhyankar B. <em>J Crohns Colitis</em>. 2016;10(12):1437-1444.</li>
                    <li>Milch C, Wyant T, Xu J, et al. <em>J Neuroimmunol</em>. 2013;264:123-126.</li>
                    <li>Briskin M, Winsor-Hines D, Shyjan A, et al. <em>Am J Pathol</em>. 1997;151(1):97-110.</li>
                    <li>Xavier RJ, Podolsky DK. <em>Nature</em>. 2007;448(7152):427-434.</li>
                </ol>

            </article>
        </div>
    </div>
</div>